embrace Active Scar Defense has been extensively studied in patients seeking to reduce the appearance of scars
Clinical trials that show you exactly what you can expect from embrace® Active Scar Defense
Multiple peer-reviewed, randomized, controlled clinical trials have demonstrated that by relieving the tension created during the healing process for weeks after surgery, embrace® can dramatically and significantly reduce the visibility of scars.
embrace® shows significant improvement in the appearance of scars
embrace® clinical trials were published in peer-reviewed journals and conducted in patients undergoing real surgical procedures. In addition, the appearance of scars was rated in a blinded fashion by independent surgeons like you who had no vested interest in the study results. Most importantly, patients were asked how satisfied they were with embrace®. And when it comes down to it, isn’t that the most important result?
Just the facts
Level 1 clinical data is the gold standard for evaluating the efficacy of a device. embrace® Active Scar Defense is the only scar treatment on the market proven effective in Level 1 trials. Learn more about clinical trials and why it matters.
of patients and doctors rated the embrace® treated side of the scar as BETTER.*
of the time, patients rated the embrace® dressing as COMFORTABLE to wear.*
of patients would RECOMMEND use of embrace® to family and friends.*
“Level 1 clinical data is prospective controlled data and is the gold standard for evaluating the efficacy of a device. Embrace® Active Scar Defense was studied in a Level 1 clinical manner and therefore shows that it’s improvement is truly related to using the device.”
Dr. Edward Miranda
Board Certified Plastic Surgeon
embrace clinical trial summary
Level 1 Randomized, peer-reviewed, controlled study
- 10 female & male patients
- used on scar revision
- 4, 6 & 12 month follow-up
- 67 female & male patients
- 12 centers
- used on Abdominoplasty
- 6 & 12 month follow-up
The embrace® device effectively minimized scarring in both the IMPROVE and REFINE clinical trials with a highly significant difference between embrace®-treated groups and control groups and control groups at both 6 months and 1 year